The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults
Open Access
- 1 January 2000
- Vol. 55 (1) , 83-85
- https://doi.org/10.1136/thorax.55.1.83
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Decreased Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in CanadaNew England Journal of Medicine, 1999
- Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacinJournal of Antimicrobial Chemotherapy, 1997
- Oral Empiric Treatment of Community-Acquired PneumoniaChest, 1996
- Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double-blind, randomised, parallel, multicentre studyJournal of Antimicrobial Chemotherapy, 1996
- Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumoniaJournal of Antimicrobial Chemotherapy, 1996
- Safety profile of sparfloxacin in the treatment of respiratory tract infectionsJournal of Antimicrobial Chemotherapy, 1996
- Torsades de pointe probably related to sparfloxacinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1996
- Community acquired pneumonia in adults: a study comparing clinical features and outcome in Africa (Republic of Guinea) and Europe (France).Thorax, 1996
- Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.1996
- Activity of CP 99, 219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepaloxacin against penicillin-susceptible and -resistant pneumococciJournal of Antimicrobial Chemotherapy, 1995